Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: A meta-analysis of 16 randomized controlled trials

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Xia, Sujian ^a   Zhang, Weidong ^b   Huang, Liting ^c   Jiang, Hong ^a  

^a JINAN UNIVERSITY   (China)

^b Novartis Pharmaceuticals Oncology   (China)

^c ZHUHAI PEOPLE S HOSPITAL ZHUHAI HOSPITAL AFFILIATED WITH JINAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; PYRIDONE DERIVATIVE; TRIAZOLE DERIVATIVE;

AGRANULOCYTOSIS; ARTHROPATHY; ARTICLE; COMPARATIVE EFFECTIVENESS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; META ANALYSIS; MONOTHERAPY; NEUTROPENIA; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; THALASSEMIA MAJOR; UNSPECIFIED SIDE EFFECT; BLOOD; COMPARATIVE STUDY; HEART STROKE VOLUME; LIVER; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; THALASSEMIA; TREATMENT OUTCOME;

BENZOATES; DEFEROXAMINE; FERRITINS; HUMANS; IRON; IRON CHELATING AGENTS; LIVER; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE VOLUME; THALASSEMIA; TREATMENT OUTCOME; TRIAZOLES;

EID: 84893461706     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082662     Document Type: Article

References (38)

1. Vichinsky EP (2005) Changing patterns of thalassemia worldwide. Ann N Y Acad Sci 1054: 18-24. PubMed: 16339647.
2. Modell B, Darlison M (2008) Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 86: 480-487. PubMed: 18568278. (Pubitemid 351821761)
3. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG et al. (1998) Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 339: 417-423. doi:10.1056/NEJM199808133390701. PubMed: 9700174. (Pubitemid 28377682)
4. Addis A, Loebstein R, Koren G, Einarson TR (1999) Meta-analytic review of the clinical effectiveness of oral deferiprone (L1). Eur J Clin Pharmacol 55: 1-6. doi:10.1007/s002280050584. PubMed: 10206077. (Pubitemid 29144092)
5. Alpendurada F, Smith GC, Carpenter JP, Nair SV, Tanner MA et al. (2012) Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major. J Cardiovasc Magn Reson 14: 8-8. doi:10.1186/1532-429X- 14-S1-P8. PubMed: 22277065.
6. Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T et al. (2007) Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemia. Clin Ther 29: 909-917. doi:10.1016/j.clinthera.2007.05.007. PubMed: 17697909. (Pubitemid 47241173)
7. Eshghi P, Molavi M, Farahmandinia Z (2011) Efficacy and safety of Iranian made Deferasirox (Osveral?) in Iranian major thalassemic patients with transfusional iron overload: A one year prospective multicentric open-label non-comparative study. Daru - Journal of Pharmaceutical Sciences.
8. Kwiatkowski JL (2011) Real-world use of iron chelators. ASH Education Program Book 2011: 451-458
9. Merchant RH, Joshi A, Ahmed J, Krishnan P, Jankharia B (2011) Evaluation of cardiac iron load by cardiac magnetic resonance in thalassemia. Indian Pediatr 48: 697-701. doi:10.1007/s13312-011-0115-9. PubMed: 21169646.
10. Viprakasit V, Lee-Lee C, Chong QT, Lin KH, Khuhapinant A (2009) Iron chelation therapy in the management of thalassemia. Asian Perspectives - Int J Hematol 90: 435-445.
11. Chang HH, Lu MY, Liao YM, Lin PC, Yang YL et al. (2011) Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia. Pediatric Blood and Cancer 56: 420-424. doi:10.1002/pbc.22826.
12. JPT H (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. In: S G, editor. The Cochrane Collaboration
13. Gomber S, Saxena R, Madan N (2004) Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassemic children. Indian Pediatr 41: 21-28. PubMed: 14767084.
14. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A et al. (2006) Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 107: 3738-3744. doi:10.1182/blood-2005-07-2948. PubMed: 16352815.
15. El-Beshlawy A, Manz C, Naja M, Eltagui M, Tarabishi C et al. (2008) Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience. Ann Hematol 87: 545-550. doi:10.1007/s00277-008-0471-2. PubMed: 18351337.
16. Galia M, Midiri M, Bartolotta V, Morabito A, Rizzo M et al. (2003) Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study. Hemoglobin 27: 63-76. doi:10.1081/HEM-120021538. PubMed: 12779268. (Pubitemid 36597401)
17. Ha SY, Chik KW, Ling SC, Lee AC, Luk CW et al. (2006) A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. Hemoglobin 30: 263-274. doi:10.1080/03630260600642617. PubMed: 16798652.
18. Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C et al. (2002) Deferiprone versus Deferoxamine in Patients with Thalassemia Major: A Randomized. Clinical Trials - Blood Cells, Molecules, and Diseases 28: 196-208. doi:10.1006/bcmd.2002.0510. (Pubitemid 34743754)
19. Smith GC, Alpendurada F, Carpenter JP, Alam MH, Berdoukas V et al. (2011) Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. Journal of Cardiovascular Magnetic Resonance 13: 1-7. doi:10.1186/1532-429X-13-S1-M1. PubMed: 21208447.
20. Aydinok Y, Ulger Z, Nart D, Terzi A, Cetiner N et al. (2007) A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major. Haematologica 92: 1599-1606. doi:10.3324/haematol.11414. PubMed: 18055982. (Pubitemid 350248238)
21. Peng CT, Chow KC, Chen JH, Chiang YP, Lin TY et al. (2003) Safety monitoring of cardiac and hepatic systems in β-thalassemia patients with chelating treatment in Taiwan*. Eur J Haematol 70: 392-397. doi:10.1034/j.1600-0609.2003.00071.x. PubMed: 12756022.
22. Piga A, Galanello R, Forni GL, Cappellini MD, Origa R et al. (2006) Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 91: 873-880. PubMed: 16818273. (Pubitemid 44023139)
23. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S et al. (2006) A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood 107: 3455-3462. doi:10.1182/blood-2005- 08-3430. PubMed: 16352812.
24. Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI et al. (2003) Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol 121: 187-189. doi:10.1046/j.1365-2141.2003.04240.x. PubMed: 12670352. (Pubitemid 36461288)
25. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA et al. (2007) A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 115: 1876-1884. doi:10.1161/CIRCULATIONAHA.106.648790. PubMed: 17372174. (Pubitemid 46598901)
26. Aydinok Y, Unal S, Oymak Y, Vergin C, Türker ZD et al. (2012) Observational study comparing long-term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation-naive children with transfusional iron overload. Eur J Haematol 88: 431-438. doi:10.1111/j.1600-0609.2012.01769.x. PubMed: 22335829.
27. Galanello R, Kattamis A, Piga A, Fischer R, Leoni G, et al. (2006) A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica 91: 1241-1243 %@ 0390-6078
28. Pantalone GR, Maggio A, Vitrano A, Capra M, Cuccia L et al. (2011) Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients. Hemoglobin 35: 206-216. doi: 10.3109/03630269.2011.570674. PubMed: 21599433.
29. Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F et al. (2009) Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. Br J Haematol 145: 245-254. doi:10.1111/j.1365-2141.2009.07609.x. PubMed: 19236376.
30. Cassinerio E, Roghi A, Pedrotti P, Brevi F, Zanaboni L et al. (2012) Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients. Ann Hematol 91: 1443-1449. doi:10.1007/s00277-012-1480-8. PubMed: 22572843.
31. Prabhu R, Prabhu V, Prabhu RS (2009) Iron overload in beta thalassemia: a review. Journal Bioscience and Technology 1: 20-31.
32. Caro JJ, Huybrechts KF, Green TC (2002) Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassemia major: a systematic review. BMC blood disorders 2: 4 %@ 1471-2326
33. Vanorden HE, Hagemann TM (2006) Deferasirox--an oral agent for chronic iron overload. Ann Pharmacother 40: 1110-1117. doi:10.1345/aph.1G566. PubMed: 16735647.
34. Mamtani M, Kulkarni H (2008) Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: a systematic review and meta-analysis. Br J Haematol 141: 882-890. doi:10.1111/j.1365-2141. 2008.07122.x. PubMed: 18355381. (Pubitemid 351724860)
35. Wood JC, Kang BP, Thompson A, Giardina P, Harmatz P et al. (2010) The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood 116: 537-543. doi:10.1182/blood-2009-11-250308. PubMed: 20421452.
36. Pathare A, Taher A, Daar S (2010) Deferasirox (Exjade®) significantly improves cardiac T2*in heavily iron-overloaded patients with β-thalassemia major. Ann Hematol 89: 405-409. doi:10.1007/s00277-009-0838- z. PubMed: 19798501.
37. Pennell DJ, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL et al. (2010) Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood 115: 2364-2371. doi:10.1182/blood-2009-04-217455. PubMed: 19996412.
38. Green D (2012) Limitations of Meta-Analyses. J Autism Dev Disord, 42: 1-2. PubMed: 21360019.